This is a prospective cohort study designed to evaluate the treatment effect as well as predictive and prognostic factors with special emphasis on the clinical utility of ctDNA in plasma in patients with gastroesophageal cancer. Patients with gastroesophageal cancer are included in 5 separate cohorts scheduled for * Surgical resection + perioperative chemotherapy (cohort 1) * Neoadjuvant chemoradiotherapy followed by surgical resection (cohort 2) * Definitive chemoradiotherapy with curative intent (cohort 3) * Systemic therapy with the intent to prolong survival (cohort 4) * Palliative treatment without the use of chemotherapy (cohort 5)
Study Type
OBSERVATIONAL
Enrollment
1,950
Measurement of circulating tumor DNA from plasma over a period of 2 years.
Rigshospitalet
Copenhagen, Denmark
RECRUITINGTime to recurrence
Time frame: 1 year
Time to progression
Time frame: 1 year
Overall survival
Time frame: 5 year
Response rate RECIST 1.1
Time frame: through study completion, an average of 1 year
Response duration RECIST 1.1
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.